en.Wedoany.com Reported - Brazilian major biological inputs manufacturer Biotrop has completed its first year of commercial operations in the U.S. market, covering 23 states, achieving customer repurchases, and accumulating revenue of $1.3 million (approximately R$6.7 million). Although this figure is modest compared to the company's total revenue of R$900 million last year, the initial result is significant given the decline in U.S. farmer incomes due to falling prices of commodities such as soybeans, wheat, and corn. According to data from the U.S. Department of Agriculture (USDA), U.S. net farm income is projected at $153.4 billion in 2026, a decrease of $4.1 billion from 2025 after adjusting for inflation; total direct government payments to U.S. farmers in 2026 are expected to reach $44.3 billion, approaching the record of $45.7 billion during the pandemic peak in 2020.
Matheus Gueratto, head of Biotrop's U.S. operations, stated that the company's primary goal in the initial phase of its U.S. operations was not revenue, but to create a user experience. Currently, hundreds of growers, distributors, and cooperatives are trialing its solutions. Biotrop's product portfolio offered to U.S. farmers includes biofungicides, bionematicides, and soil conditioners, covering large-acre crops such as soybeans, corn, wheat, cotton, and peanuts, with 13 products already registered in the U.S. Gueratto believes that the company's operational history accumulated in Brazil helps overcome the resistance of U.S. farmers, which stems from inconsistent past experiences with biological products.
Biotrop has 13 professionals in the U.S., six of whom work in the field, distributed across the U.S. peanut production region (southern Georgia, northern Florida, and eastern Alabama, accounting for approximately 70% of U.S. peanut production), the Corn Belt, and the Mississippi River Valley (growing soybeans, corn, cotton, peanuts, and rice). Farmers who used Biotrop products during the 2025 growing season increased their repurchase quantities in the following season.
In terms of long-term planning, Biotrop aims to achieve $160 million in revenue in the U.S. by 2034, which requires maintaining a high annual growth rate of approximately 70%. Gueratto stated that this target is based on a solid business plan and that the U.S. market itself will grow. The company's preparations in the U.S. began before the arrival of the commercial team: by the end of 2024, it had established an R&D center at the University of Florida's innovation hub, UF Innovate (located in Gainesville), which became the U.S. headquarters. Current partners also include the University of Georgia, Iowa State University, North Dakota State University, and Louisiana State University. Biotrop plans to invest between $12 million and $15 million in U.S. R&D, with funds allocated based on market demand and no specific timeline set. Currently, most products sold in the U.S. are imported from Brazil, but Gueratto indicated that local manufacturing would be considered when conditions permit in the future.
Beyond the U.S. market, Biotrop has entered the Canadian market, registering three products and conducting field trials, with sales expected to begin in the 2027 growing season. At the end of 2025, its Belgian holding group, Biofirst, incorporated another U.S. subsidiary, Bioworks, under Biotrop. Bioworks focuses on biological solutions for fruit and vegetable crops. This acquisition brought in approximately €20 million (slightly over R$120 million) in revenue, 40 professionals in the U.S., 16 professionals in Europe, and additional production units. Gueratto stated that Bioworks operates in parallel with Biotrop in the U.S., with the goal of mutually accelerating progress in terms of product portfolio, technology, and synergies.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
